These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23672220)

  • 21. Effects of acarbose treatment in Type 2 diabetic patients under dietary training: a multicentre, double-blind, placebo-controlled, 2-year study.
    Hasche H; Mertes G; Bruns C; Englert R; Genthner P; Heim D; Heyen P; Mahla G; Schmidt C; Schulze-Schleppinghof B; Steger-Johannsen G
    Diabetes Nutr Metab; 1999 Aug; 12(4):277-85. PubMed ID: 10782754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
    Derosa G; Franzetti I; Querci F; D'Angelo A; Maffioli P
    Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
    Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC
    Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44).
    Holman RR; Cull CA; Turner RC
    Diabetes Care; 1999 Jun; 22(6):960-4. PubMed ID: 10372249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed Type 2 diabetes.
    Bao YQ; Zhou J; Zhou M; Cheng YJ; Lu W; Pan XP; Tang JL; Lu HJ; Jia WP
    Clin Exp Pharmacol Physiol; 2010 May; 37(5-6):564-8. PubMed ID: 20082624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients.
    Duran C; Tuncel E; Ersoy C; Ercan I; Selimoglu H; Kiyici S; Guclu M; Erturk E; Imamoglu S
    J Endocrinol Invest; 2009 Jan; 32(1):69-73. PubMed ID: 19337019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.
    Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH; Wolever TM
    Ann Intern Med; 1994 Dec; 121(12):928-35. PubMed ID: 7734015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses.
    Fischer S; Hanefeld M; Spengler M; Boehme K; Temelkova-Kurktschiev T
    Acta Diabetol; 1998 Apr; 35(1):34-40. PubMed ID: 9625287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acarbose vs. bedtime NPH insulin in the treatment of secondary failures to sulphonylurea-metformin therapy in type 2 diabetes mellitus.
    López-Alvarenga JC; Aguilar-Salinas CA; Velasco-Perez ML; Arita-Melzer O; Guillen LE; Wong B; Brito G; Mercado V; Gómez-Pérez FJ; Rull-Rodrigo JA
    Diabetes Obes Metab; 1999 Jan; 1(1):29-35. PubMed ID: 11221809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.
    Coniff RF; Shapiro JA; Seaton TB
    Arch Intern Med; 1994 Nov; 154(21):2442-8. PubMed ID: 7979840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.
    Rosenstock J; Brown A; Fischer J; Jain A; Littlejohn T; Nadeau D; Sussman A; Taylor T; Krol A; Magner J
    Diabetes Care; 1998 Dec; 21(12):2050-5. PubMed ID: 9839093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors that influence the efficacy of acarbose and metformin as initial therapy in Chinese patients with newly diagnosed type 2 diabetes: a subanalysis of the MARCH trial.
    Zhang J; Wang N; Xing X; Yang Z; Wang X; Yang W
    Curr Med Res Opin; 2016; 32(4):713-9. PubMed ID: 26714411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study.
    Hotta N; Kakuta H; Sano T; Matsumae H; Yamada H; Kitazawa S; Sakamoto N
    Diabet Med; 1993 Mar; 10(2):134-8. PubMed ID: 8458189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients.
    Delgado H; Lehmann T; Bobbioni-Harsch E; Ybarra J; Golay A
    Diabetes Metab; 2002 Jun; 28(3):195-200. PubMed ID: 12149599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group.
    Costa B; Piñol C
    Diabetes Res Clin Pract; 1997 Oct; 38(1):33-40. PubMed ID: 9347244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acarbose improves glycemic control in insulin-treated Asian type 2 diabetic patients: results from a multinational, placebo-controlled study.
    Hwu CM; Ho LT; Fuh MM; Siu SC; Sutanegara D; Piliang S; Chan JC;
    Diabetes Res Clin Pract; 2003 May; 60(2):111-8. PubMed ID: 12706319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of acarbose on insulin sensitivity in elderly patients with diabetes.
    Meneilly GS; Ryan EA; Radziuk J; Lau DC; Yale JF; Morais J; Chiasson JL; Rabasa-Lhoret R; Maheux P; Tessier D; Wolever T; Josse RG; Elahi D
    Diabetes Care; 2000 Aug; 23(8):1162-7. PubMed ID: 10937515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postmarketing surveillance of acarbose treatment in Taiwanese patients with type 2 diabetes mellitus.
    Hung YJ; Kuo SW; Wang CH; Chang HY; Hsieh SH; Landen H
    Clin Drug Investig; 2006; 26(10):559-65. PubMed ID: 17163289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
    Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.